Fresenius Kabi announced the launch of Micafungin for Injection, a generic version of Mycamine (micafungin for injection; Astellas Pharma).

Micafungin, a member of the echinocandin class of antifungal agents, is indicated for the treatment of:

  • Candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses in adult and pediatric patients aged ≥4 months.
  • Candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients aged <4 months.
  • Esophageal candidiasis in adult and pediatric patients aged ≥4 months.
  • Prophylaxis of Candida infections in adult and pediatric patients aged ≥4 months undergoing hematopoietic stem cell transplantation (HSCT).

“We’re pleased to offer the first Micafungin generic in the United States, expanding our anti-infective portfolio, and increasing supply of this much-needed medication.” said John Ducker, president and CEO of Fresenius Kabi USA.

The product is available in 50mg and 100mg single-dose vials.

For more information visit fresenius-kabi.com.